Lexaria Bioscience Corp. announced on June 23, 2025, that it has received two new international patents, bringing its total worldwide patent portfolio to 50. This achievement marks a significant milestone envisioned by the company's management for over a decade.
One new patent was granted in Australia within its patent family #24, 'Compositions and Methods for Treating Epilepsy', broadening intellectual property protection outside the USA. This patent will expire in 2044, covering a market valued at US$9.5 billion in 2023 and expected to reach over $15 billion by 2032.
Additionally, a new patent was granted in Japan within its patent family #20, 'Compositions and Methods for Sublingual Delivery of Nicotine', expiring in 2043. This expands Lexaria's protection in the global retail oral nicotine market, which was valued at US$5.5 billion in 2023 and is projected to grow at 26% annually until at least 2030.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.